Member Info for bogyo

I am not expecting a pump and dump spike on this news but a continuous rise and shifting to a bull trend on the SP. Upward targets will be reached this year, and I believe we will be in double figures soon. Contract news will spike this up and Broker targets will be multiplied as we go along. Neither Cenkos nor Stifel are accounting for any potential news or continuous contract wins in their figures. The only way is substantially up from here.

RossC, I think Cenkos just picked randomly two production examples Ford Mach-E and F150. Really nothing to read into it... :)

haha, most important bit was missed:

"Management team is delivering in a tough environment – despite a longer road to recovery from the pandemic for most sectors, especially those exposed to transportation markets, Seeing Machines is now demonstrating both a resilient top line performance and an ability to manage the business for cash, helping support our revenue growth expectations and increasing the potential to run the business to self-funding without the need for issuing further equity. "

"Better trading than expected

Seeing Machines has released a trading update demonstrating the
business is performing better than expected on key metrics: Revenues of
A$39.7m were 13% ahead of our expectations of $35.1m and cash of
A$38.7m was 21% ahead of our expectations of A$32.0m. We believe
this strong end to the financial year reflects the continued demand for
the company’s Fleet product by sophisticated fleet owners and that the
key home markets of Australia and New Zealand have been less affected
by COVID than feared. We believe this strong cash performance should
reduce the perceived funding risk weighting and help the valuation
recover towards previous levels. We iterate our Buy recommendation
and 7.2p price target.

Fleet installation rate back on track - Whilst the headline figure for installed units
by the year end is only 2% ahead of our expectations, it still represents 46% growth
YoY which is impressive considering the pressures on fleet owners this year. Also,
more importantly the rate of installations has significantly increased in the last few
weeks of the financial year from lows of 50/month at the height of the pandemic
lockdowns up to a rate of 250/month and rising. The helps support our view that
this business unit could grow revenues by more than 35% in FY21

Automotive product launches will increase visibility – With the launch of two
globally significant vehicles incorporating Seeing Machines driver monitoring in the
coming months, we believe value attributed to this business by the market will rise
despite COVID likely delaying some new RFQ activity. We also note that with
production systems in place at key global OEMs, new RFQs are not necessarily
needed by the OEMs as they roll the technology out to other platforms in their group,
as demonstrated by Ford putting DMS into the Mach-E as well as the F150.

Cash is king and the balance is healthy - The cash position at the year-end of
A$38.7m implies a significant reduction in the operating cash burn in the second half
to cA$8m from A$15m in the first half (we believe the company has not materially
increased its small debt positions). In addition to the better than expected revenues,
we believe the positive cash outperformance reflects the continued unwinding of
working capital in the fleet division as well as the diligent focus of the management
on cost control as well as the salary sacrifices made across the firm. The cash balance
reported is A$6.7m greater than we expected and now looks to cover the A$5.5m
cash shortfall previously forecast.

Management team is delivering in a tough environment – despite a longer road to recovery from the pandemic for most sectors, especially those exposed to transportation markets, Seeing Machines is now demonstrating both a resilient top line performance and an ability to manage the business for cash, helping support our revenue growth expectations and increasing the potential to run the bus

"Seeing Machines has released a trading update demonstrating the
business is performing better than expected on key metrics: Revenues of
A$39.7m were 13% ahead of our expectations of $35.1m and cash of
A$38.7m was 21% ahead of our expectations of A$32.0m. We believe
this strong end to the financial year reflects the continued demand for
the company’s Fleet product by sophisticated fleet owners and that the
key home markets of Australia and New Zealand have been less affected
by COVID than feared. We believe this strong cash performance should
reduce the perceived funding risk weighting and help the valuation
recover towards previous levels. We iterate our Buy recommendation
and 7.2p price target. "

What a great news! I do expect the SP to substantially move up from here. The biggest risk was this trading result and the imposed risk of any later funding need. This was the main reason the SP is sitting here. Looks now cash risk is way over and the SP is free to move to upper targets.

So its the same from a week ago. Appreciative to make it available to all investors. Also an acknowledgement of the researchers speculations and views.

I wonder if this will be a new research note or the same issued a week ago by SP Angel. That was quite a thorough note

they got it wrong a couple of times and I think the last one was due to the slow ranging move on below a few indicators. Based on todays action I would expect a long signal when the daily closes above the 100 MA. and then they will stay bullish and all will jump long because it will ignite many lagging indicators to buy.

It is what we wanted to see ahead of any expected news, volume increase on buying and large accumulation.
This is a no brainer opportunity and it will bring in the larger investments.
Pop is imminent

There is certainly an accumulation going on and imo it will pop soon.

Volume looks very supportive from today, consolidated and holding well to break up on Monday.

also the note on humanised mice:
"Immugenyx, LLC, the subsidiary developing the model, has multiple ongoing collaborations in place including ones with Johnson & Johnson, Orgenesis and an unnamed major biopharma company (GlobalCo)."

Looks more to me than just a copy/paste error. This is actually all over the doc.
Maybe they should call them Globalco 1,2,3 etc or they just want to announce in another RNS that that Globalco2 is again Eli Lilly, LOL

Then either the RNS was wrong or the current Research note, as it clearly states the 2 as separate:
"Alongside these developments, the Group continues to make progress across its existing asset pipeline of treatments including its CDX antibody programme, for which the Company is concluding discussions with an unnamed multinational biopharmaceutical company (GlobalCo), which could result in a significant licencing agreement."

coming back to this question as I dont think this is actually clear.

The SP Angel note still talks about GlobalCo in relation to the CDX research. So does this mean this is a different Global Pharma Company? Eli is mentioned in a different agreement as announced with lupus research.

"CDX platform: The collaboration with an unnamed major biopharma (GlobalCo) regarding the CDX antibody platform is nearing its conclusion."

RNS is always tomorrow
by now you should have know that, otherwise it would not be a discussion because it was today.

Where are the 2 months timeline coming from?
2 months would be normal approval timelines, but under EUA, it seems too long even with a delay due to increase in applications.

these larges were printed as sells but then the price moved up, so really unsure if 3p was today sell or not. 2.95 probably was earlier.
closed nicely at 3.06 thanks to freetrade.
hope tomorrow continues this break through.

I was reading this note in the morning and so funny, but this is basically the same info what Vlad shared during the Webinar, just put into nice publishable note with backed up analysis.
SP Angel note says "looking to strike a partnership" in Vlad words - "no partner"
SP Angel says for Covid "We would expect significant interest in the candidate" Vlad says "not yet collaborating"
etc.
And a lot of focus is shared about similar companies and their success and mcap potential, where we are currently under performing.
To my knowledge they did not share the Webinar recording, and this is for the best. This note is well written and is presentable.
Reading this is much more convincing and hopefully will stop the SP dropping due to Investors concern.

So hvgd comes here occasionally throws some fundraising **** while he believes the sp will perform x2 and rise to his average to get out.
Your posts do not reflect what you are actually doing.
There are many who would like to buy your shares at this price.

Ice, indeed the support zone at 6.9p-7p but I think thats the top of it and the zone extends to 6.5-6.6p Anyway touched 7p so this might have just been it.
I would not worry on this slide, it is now back to corrective ranging but probably might slip down a bit more. There is no real selling or buying power yet, so I would assume just a search for liquidity and finding people under 7p ahead of any news expectations.
Upside is plenty of potential. Hold and dont look on minuscule movements.
Anything under 7p is a strong buy, as always.